Singapore, May 28 -- ImmunityBio, Inc., a leading immunotherapy company, has announced the signing of a strategic Memorandum of Understanding (MoU) with the Ministry of Investment of Saudi Arabia (MISA), King Faisal Specialist Hospital & Research Centre (KFSHRC), and King Abdullah International Medical Research Center (KAIMRC).

This multi-party collaboration will introduce the US FDA-approved Cancer BioShield platform to Saudi Arabia and the broader Middle East, paving the way for a new era of immune-restorative therapies for cancer patients.

The announcement was made during the Saudi-US Investment Forum 2025 in Riyadh, held alongside the state visit of US President Donald Trump.

The BioShield platform, powered by Anktiva(R) (nogapende...